Tufts Clinical and Translational Science Institute

Demystifying Cancer Clinical Trials

Clinical Trials From PI-Initiated to Collaborative Research



Tufts Clinical and Translational Science Institute

Team Science & Engaging with Industry

Andrew Evans, DO, MSc

Director, Tufts Cancer Center Chief, Division of Hematology/Oncology Director, Lymphoma Program Professor, Tufts University School of Medicine

Robert E. Martell, MD, PhD

Medical Oncologist Tufts Medical Center Associate Professor Tufts University School of Medicine



Tufts Clinical and Translational Science Institute

Team Science (Collaboration): In Academics, Clinical Research, and Grants

Dr. Andy Evens

Team Science/Collaborations: AGENDA

- Cultivating Collaborations/Team Science 101
- Team Science in Clinical Studies
- Team Science in Grants

Why Do I Want a Collaborator?

- I can't do/know everything myself
 - Both clinical medicine and basic science are becoming increasingly complex and separated by an increasing chasm¹
- More meaningful clinical trials
 - Clinical research is perceived as poorer quality than basic science²
 - More efficient use of funding/dollars³
- Access to different funding sources
 - E.g., NIH, Foundations

Portilla. Sci Transl Med 2010;2
 Campbell. JAMA 2001; 286(7):800
 McCammon. Sci Tranl Med 2012;4

Collaborations Pearls

- Very difficult to do it alone
- Utilize different avenues to find/establish collaborations (e.g., ASH/ASCO, Cooperative Groups, Small venues/meetings)
- Try find a scientist and/or pathologist to collaborate with
- Don't always expect 1st author

Barriers to Collaboration¹

- Infrastructure
 - Limited access to qualified investigators
 - Limited access to technology
- Resources
 - Increased costs/share revenue
 - Limited funding (not supported by industry)
- Academic culture
 - Authorship
 - Intellectual property (industry partners)
 - Time sink
 - Loss of focus
- Regulatory impediments
 - Within academic institutions
 - From industry (IP issues)

- Collaborators within the institution
- Collaborators at other academic institutions

 Including International
- Collaborators in industry/pharma
- Collaborations with community oncology!

Collaborations within the Institution

- Advantages
 - Proximity
 - Better revenue/resource sharing
- Disadvantages
 - Limited selection of investigators/technologies
 - Hard feelings if things don't work out or collaborators don't fulfill commitments

Lessons I learned: Finding a collaborator

- Volume and diversity are important
 - Get used to writing study concepts quickly and frequently.
- Find someone you'd like to work with and then find a shared goal
 - seems a backwards, but it may be the more realistic strategy
- Decide what you want to do and then find a collaborator
 - You might get lucky and find someone doing exactly what you need help with
- Offer your services as a collaborator
 - Translational/lab people are often looking for clinical collaborators but aren't sure where to find them
- Attend other peoples meetings
 - Meet as many people as you can and get to know what they like

Lessons I learned: Maintaining a collaboration

- If something (project/relationship) is working, keep working on it
 - If you don't really like it, stop
- What do you bring to the collaboration?
 - Data? Samples? Clinical perspective?
 - Be a gatekeeper to something
- Don't just be the delivery guy/girl
 - Try to contribute something to the project
- Time
 - Be prepared to carve out a large piece of time; regular, in person meetings are important
- Define roles
 - Agree on action plans

Collaborations with Other Institutions

- Advantages
 - More likely to find someone in your field
 - Increase sample size
 - Increase validity coming from multicenter study
- Disadvantages
 - Less in-person communication
 - Cost/revenue sharing
 - Challenges convincing funding agencies of successful collaboration

Examples of collaborations with other institutions

CLINICAL TRIALS AND OBSERVATIONS

Brief report

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era

Andrew M. Evens,¹ Irene Helenowski,² Erika Ramsdale,³ Chadi Nabhan,⁴ Reem Karmali,⁵ Britt Hanson,⁶ Benjamin Parsons,⁴ Scott Smith,⁶ Annette Larsen,¹ June M. McKoy,⁷ Borko Jovanovic,² Stephanie Gregory,⁶ Leo I. Gordon,⁸ and Sonali M. Smith³

¹Division of Hematology/Oncology, University of Massachusetts Medical School, Worcester, MA; ²Department of Preventive Medicine, Northwestern University, Chicago, IL; ³Department of Medicine, Division of Hematology/Oncology, University of Chicago Hospitals, Chicago, IL; ⁴Department of Medicine, Division of Hematology/Oncology, University of Chicago Hospitals, Chicago, IL; ⁴Department of Medicine, Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL; ⁶Division of Hematology/Oncology, Lovola University Medical Center, Maxwood, IL; ⁷Division of Geriatric Medicine, Feinberg School of Medicine, Northwestern University,

Chicago,

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era

Andrew M. Evens, Kevin A. David, Irene Helenowski, Beverly Nelson, Dixon Kaufman, Sheetal M. Kircher, Alla Gimelfarb, Elise Hattersley, Iauren A. Mauro, Borko Jovanovic, Amy Chadburn, Patrick Stiff, Jane N. Winter, Jayesh Mehta, Koen Van Besien, Stephanie Gregory, Leo I. Gordon, Jamile M. Shammo, Scott E. Smith, and Sonali M. Smith

Examples of collaborations with other institutions

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

Hypoxia-Inducible Factor-1 α Expression Predicts Superior Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP

ndrew M. Evens, Laurie H. Sehn, Pedro Farinha, Beverly P. Nelson, Adekunle Raji, Yi Lu, Adam Brakman, amsi Parimi, Jane N. Winter, Paul T. Schumacker, Randy D. Gascoyne, and Leo I. Gordon

research paper

Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome

Chadi Nabhan,1 Sonali M. Smith,2 Irene Summary Helenowski,3 Erika Ramsdale,2 Benjamin Parsons,4 Reem Karmali,5 Josephine Feliciano,6 Britt Hanson,4 Scott Smith,4 June McKoy,⁷ Annette Larsen,⁸ Andrew Hantel,5 Stephanie Gregory5 and Andrew M. Evens⁸

¹Division of Hematology/Oncology, Department of Medicine, Advocate Lutheran General Hospital, Park Ridge, ²Division of Hematology/Oncology, Department of Medicine, University of Chicago Hospitals, ³Department of Preventive Medicine, Northwestern University, Chicago, ⁴Division of Hematology/Oncology, Loyola University Medical Center, Maywood, ⁵Division of Hematology, Rush University Medical Center, ⁶Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, 7 Division of Geriatric Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, and ⁸Division of Hematology/Oncology, University of Massachusetts Medical School, Worcester, MA, USA

Data on outcome, prognostic factors, and treatment for very elderly non-Hodgkin lymphomas (NHL) is sparse. We conducted a multicentre retrospective analysis of NHL patients ≥80 years (at diagnosis) treated between 1999 and 2009. Detailed characteristics were obtained including geriatric syndromes, activities of daily living (ADLs), and co-morbidities using the Cumulative Illness Rating Scale-Geriatrics (CIRS-G). We identified 303 patients: 170 aggressive NHL (84% B cell/16% T cell) and 133 indolent NHL (82% B cell/18% T cell). Median age was 84 years (80-95). A geriatric syndrome was present in 26% of patients, 18% had ≥1 grade 4 CIRS-G, and 14% had loss of ADLs. At 49-month median follow-up, 4-year progressionfree (PFS) and overall survival (OS) for aggressive NHLs were 31% and 44% respectively (stage I/II: PFS 53% and OS 66%; stage III/IV: PFS 20% and OS 32%; P < 0.0001 and 0.0002, respectively). Four-year PFS and OS for indolent NHL were 44% and 66% respectively, regardless of stage. Multivariate regression analysis identified two key factors that predicted inferior PFS and OS for both NHL groups: lack of CR and loss of ADLs. Prospective studies for very elderly NHL that incorporate geriatric tools, especially ADLs, are warranted.

Keywords: non-Hodgkin lymphoma, elderly, geriatric syndromes, functional status, co-morbidities.

Examples of collaborations with other institutions

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis

Andrew M. Evens, Ranjana Advani, Oliver W. Press, Izidore S. Lossos, Julie M. Vose, Francisco J. Hernandez-Ilizaliturri, Barrett K. Robinson, Stavroula Otis, Liat Nadav Dagan, Ramsey Abdallah, Aimee Kroll-Desrosiers, Jessica L. Yarber, Jose Sandoval, Kelley Foyil, Linda M. Parker, Leo I. Gordon, Kristie A. Blum, Christopher R. Flowers, John P. Leonard, Thomas M. Habermann, and Nancy L. Bartlett

A B S T R A C T

Purpose

Lymphoma is the fourth most frequent cancer in pregnancy; however, current clinical practice is based largely on small series and case reports.

Patients and Methods

In a multicenter retrospective analysis, we examined treatment, complications, and outcomes for Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) occurring during pregnancy.

Results

Among 90 patients (NHL, n = 50; HL, n = 40), median age was 30 years (range, 18 to 44 years) and median diagnosis occurred at 24 weeks gestation. Of patients with NHL, 52% had advanced-stage versus 25% of patients with HL (P = .01). Pregnancy was terminated in six patients. Among the other 84 patients, 28 (33%) had therapy deferred to postpartum; these patients were diagnosed at a median 30 weeks gestation. This compared with 56 patients (67%) who received antenatal therapy with median lymphoma diagnosis at 21 weeks (P < .001); 89% of these patients received combination chemotherapy. The most common preterm complication was induction of labor (33%). Gestation went to full term in 56% of patients with delivery occurring at a median of 37 weeks. There were no differences in maternal complications, perinatal events, or median infant birth weight based on deferred versus antenatal therapy. At 41 months, 3-year progression-free survival (PFS) and overall survival (OS) for NHL were 53% and 82%, respectively, and 85% and 97%, respectively, for HL. On univariate analysis for NHL, radiotherapy predicted inferior PFS, and increased lactate dehydrogenase and poor Eastern Cooperative Oncology Group performance status (ECOG PS) portended worse OS. For HL patients, nulliparous status and "B" symptoms predicted inferior PFS.

Conclusion

Standard (non-antimetabolite) combination chemotherapy administered past the first trimester, as early as 13 weeks gestation, was associated with few complications and expected maternal survival with lymphoma occurring during pregnancy.

J Clin Oncol 31:4132-4139. @ 2013 by American Society of Clinical Oncology

Andrew M. Evena, Tufta University School of Medicine, Boston; Aimee Kroll-Deerosiers, University of Massechusetts Medical School, Worcester, MA: Renjane Adveni and Stavroule Otia, Stanford University Medical Center, Stanford CA: Oliver W. Press and Linde M. Parker, Fred Hutchinson Cancer Research Center, Seattle, WA; Indone S. Losson, List Nedev Degen, and Jose Sandoval, University of Miami School of Medicine, Miami, FL; Julie M. Vose, University of Nebraska Medical Center, Ornaha, NE; Francisco J. Hernandez-lizaliturri, Roswell Park Cancer Institute, Buffalo: Rameey Abdelleh and John P. Leonard, Weill Cornell Medical College, New York, NY: Berrett K. Robinson, Indiana University School of Medicine, Indianapolia, IN; Jessica L. Yarber and Leo I. Gordon. Northwestern University Feinberg School of Medicine, Chicago, IL; Kristie A. Blum, The Ohio State University, Columbus, OH: Christopher R. Flowers, Emory University, Atlanta, GA; Thomas M. Habermann, Mayo Clinic, Rochester, MN; and Nency L. Bertlett, Weshington University School of Medicine, St. Louis, MO.

Published online aheed of print at www.jco.org on September 16, 2013.

Presented at the 11th International Conference on Malignent Lymphorme, Lugano, Switzerland, June 15-18, 2011, and the 53rd American Society of Hamatology Annual Meeting and Expoation, San Francisco, CA, December 11:10: 2011

Team Science: Clinical Research

Implementing a protocol

- Big picture
 - GCP
 - Project management

Details

- Protocol training
- Data management
- Ongoing regulatory work (IRB, DSMB, FDA)

• (S)AEs, deviations/waivers, amendments

- Other sites?
- Drug accountability
- CROs/monitors (industry studies)
- Incorporation of translational/laboratory science
 - Lab manual
 - Team work

It takes a village ...

- Clinical investigators _____
- PA/NPs

- YOU
- Research nurse
- Data manager
- Regulatory manager
- Investigational drug pharmacist

- Research phlebotomist
- Budget personnel
- Statistician
- Translational scientists
- Referring physicians
- Patients

Finding the right people

- If you assemble your own team
 - Concerned about and committed to the project
 - Enthusiastic, proactive
 - Can devote time to the initiative
 - Have the right skills
- If you work with an existing team
 - Consider benchmarks
 - Give feedback often
 - Define all roles, including your own
 - Practice listening
 - Communicate effectively
 - Don't make decisions without all the information

Teams can and do fail

- Excessive work load
- Team leaders do not control individual team members
- Inadequate resources
- Frequent changes in team makeup (RETENTION)
- Purpose of team is not clear
- Inadequate planning
- Many other reasons!

Investigator Responsibilities



Multi-site IST

- As the study sponsor/PI, you are responsible for the conduct of the study at other sites.
- Consider developing an office policy that includes the following details for all studies (all of which can be done via phone/internet):

- Site initiation visit, monitoring plan, close out visit

- Consider developing a protocol-specific strategy for communication between sites.
 - Teleconference, group email, etc.



- The study sponsor (holder of the IND) is responsible for submitting the following to the FDA:
 - Protocol amendments
 - IND safety reports must be provided to FDA and all participating sites.
 - Mandatory reports (serious and unexpected)
 - MedWatch forms (3500A if you hold the IND)
 - Timing depends on severity (7 vs. 15 days)
 - Initial report and follow up report
 - Annual IND report
 - The FDA will not remind you
 - This keeps going as long as the protocol is open
 - E.g., upfront RIT study closed after 5 subjects but we are committed to reporting for 5 years

IRB

- The PI at each site is responsible for submitting the following to the IRB:
 - Continuing reviews usually annually
 - Cumulative AEs (toxicity log)
 - Violations/deviations
 - Amendments
 - Updates to IB
 - Deviations/planned deviations
 - SAEs
 - Each IRB has a policy regarding SAE reporting



- DSMB reports are defined by DSMP
- DSMP should be defined in advance and should include the following:
 - Data to be included
 - E.g., safety, efficacy, enrollment
 - Timing of submissions
 - Stopping rules
 - Which DSMB will be used
- Recommend a DSMB for all investigator-initiated (at least phase II and phase III trials)

CRO/Monitor

- CROs work for the study sponsor to ensure that the study is completed rapidly, that the protocol is followed, and that the data is accurate
- CROs provide some distance between industry and the study
- CROs are paid large sums of money and must justify their existence by doing a good job and sometimes by creating work that may not be relevant
- Despite the largely adversarial relationship, monitors are not the enemy; take time to meet them (but not too much)
- Be ready to intervene if there are issues between the monitor and the regulatory coordinator/data manager

Does all the work pay off??

Cancer Therapy: Clinical

The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [⁹⁰Y]lbritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial

Andrew M. Evens,¹ William G. Spies,² Irene B. Helenowski,³ David Patton,¹ Stewart Spies,² Borko D. Jovanovic,³ Sarah Miyata,¹ Elizabeth Hamilton,¹ Daina Variakojis,⁴ Jun Chen,⁵ Louie Naumovski,⁵ Steven T. Rosen,¹ Jane N. Winter,¹ Richard A. Miller,⁵ and Leo I. Gordon¹

Team Science: Grants

Scientific Grant Opportunities

- R01 (up to 5 years), R21 (1-2 years), and R03 (1-2 years)
 - <u>R01</u>: Clinical Oncology (C-ONC) section (\$250,000 per year in direct costs)
 - <u>R21</u>: Exploratory/Developmental Research Grant Award; no "parent" awards; combined budget for direct costs for the two year project period may not exceed \$275,000 (no renewals)
 - <u>R03</u>: Pilot or feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; development of new research technology (\$50,000/year)

R01: Specific Aims (example)

- <u>Aim 1</u>: To investigate the lethality and mechanistic importance of suppressing MEK/ERK and downstream substrates (e.g., MCT-1) with a potent 2nd generation MEK inhibitor alone and with rational combinations in B-cell and T-cell NHL cells, *in vivo* xenografts, and tumor graft models.
- <u>Aim 2</u>: To determine global alterations in translation (translational profile) within B- and T-cell lymphoma cell lines and primary lymphoma samples following exposure to small molecule MEK inhibitor therapy alone and in combination, compared with shRNA MCT-1 and MEK-2 KO's.
- <u>Aim 3</u>: To complete a phase II clinical trial for patients with relapsed/refractory DLBCL using single-agent AZD6244 Hydrogen-Sulfate formulation anti-MEK therapy to determine clinical efficacy and investigate novel biomarkers of resistance and response (*clinicaltrials.gov* NCT01278615).

Scientific Grant Opportunities (cont)

- <u>R41/42</u>: Small Business Technology Transfer (STTR) or <u>R43/44</u>: Small Business Innovative Research (SBIR)
 - Assists small business and research communities in commercializing innovative technologies
 - Three-phase structure:
 - I Feasibility study to establish scientific/technical merit of the proposed R/R&D efforts (generally, 1 year; \$150,000)
 - II Full R/R&D efforts initiated in Phase I (generally 2 years; \$1,000,000)
 - III- Commercialization stage (cannot use STTR funds)

Scientific Grant Opportunities (cont)

- DoD
- VA Merit (Hematology Section)
- National Heart Lung and Blood Institute (NHLBI), AHA, DoE, etc
- FDA Orphan Drugs (OOPD)
 - E.g., Phase 1 Study of Umbilical Cord Blood Derived CD19 Specific T cell Therapy in the Treatment of Advanced B Cell Malignancies— \$600,000 over three years (MDACC)

"Team" Grants

- P01 (Program Projects)
- U01 (Consortiums)
- SPORE (Specialized Program of Research Excellence)
- Specialized Center of Research (SCOR) program (Leukemia and Lymphoma)

Niche Grant Opportunities

- Institutional (esp. CTSIs and Cancer Centers)
- Patient-Centered Outcomes Research Institute (PCORI)
- Industry grants (usually Ad Hoc and more scientific- lab or correlative studies)

Summary

- Finding and cultivating collaborators/teams takes time and persistence
- Teams take many forms (clinicians, stats, pathologists, lab scientists, industry, etc)
- Leverage team science for: retrospective projects, clinical trials, grants, etc
- Maintaining collaborations takes insight, work, and leadership (esp. clin. Trials)
- All for one and one for all!



QUESTIONS?
Team Science and Engaging with Industry

Robert Martell, MD, PhD Tufts Medical Center

Ecosystem of Company-Run Studies

| <u>Academic</u> | Company | <u>CRO #1</u> | <u>CRO #2</u> |
|--------------------|-----------------------|---------------------|-------------------|
| Lead Investigators | Clinical Strategy | Medical Monitor | Pharmacovigilance |
| Investigators | Biostatistics | Clinical Operations | Imaging |
| Scientists | Biology | | ECG |
| | Regulatory | | |
| | Clinical Pharmacology | | |
| | Medical Monitor | | |
| | Clinical Operations | | |
| | Pharmacovigilance | | |
| | Data Management | | |
| | Medical Affairs | | |
| | Commercial | | |

Physicians in the Pharmaceutical Industry



Translational/Early Drug Development Physician

- Identify targets and develop assays
- Develop biomarker assays and strategies
- Design/implement phase 1 studies
- Monitor safety



Medical Monitor

- Design & implement phase I-III studies
- Work closely with investigators
- Monitor safety
- Clinical development strategy



Medical Affairs

- Work with Investigators to design & implement studies to expand label
- Develop physician and investigator relationships geared to better utilization of a drug
- Ensure marketing material is appropriate



Pharmacovigilance

- Monitor safety events and aggregate safety data
- Ensure appropriate regulatory reporting
- Implement appropriate safety controls
- Assess signals relative to known data



Regulatory Physician

- Prepare regulatory documents
- Advise on FDA/EMA processes and precedents
- Develop registrational strategy
- Interact with regulatory authorities



Navigating Pharma to Gain Access to Novel Molecules

• Before reaching out

- Develop thorough understanding of the molecule, including MOA, PD, PK
- Develop concept: creative, compelling, but also <u>rational</u> and <u>practical</u>
 - » Identify an indication not yet pursued
 - » FDA approvable indication; Map studies required
 - » Include correlative studies (identify collaborator)
- Organize data you (or others) have with related molecules and relevant assays
- Consider what needed
 - » Amount of drug needed for clinical study (and/or preclinical studies)
 - » Budget
 - Drug only
 - Drug + <\$100k (or \$5k/patient)
 - Drug + \$30k per patient
 - » Investigator IND (vs Company IND)

Navigating Pharma to Gain Access to Novel Molecules (cont.)

• General Principles

- Lack of responsiveness from one person doesn't mean lack of interest from company
- The company can't guide you
- Network within company
 - Medical Affairs: Local representative, Physician, Head of Med Affairs
 - Development: Clinical Strategy, Head of Medical Development, Medical Director
 - Non-Clinical: Biology lead, Scientist
 - Commercial: Sales rep
 - Corporate Leaders: CEO, CMO, President

Thank You



Tufts Clinical and Translational Science Institute

Food and Drug Administration (FDA)

Andreas Klein, MD

Director, Hematologic Malignancies Program Assistant Director, Bone Marrow and Hematopoietic Cell Transplant Program Chair, Tufts Health Sciences Campus Institutional Review Boards Associate Professor, Tufts University School of Medicine

Robert E. Martell, MD, PhD

Medical Oncologist Tufts Medical Center Associate Professor Tufts University School of Medicine



Tufts Clinical and Translational Science Institute



Robert Martell, MD, PhD Tufts Medical Center

IND (Investigational New Drug)

- Request for authorization from the FDA to administer an investigational drug or biological product to humans
 - Once IND is open clinical testing can be done
 - All treatment of people prior to FDA approval is done under an IND; after approval, research continues to be done under an IND
 - Single patient or compassionate use IND
- Includes
 - Animal study data and toxicity data
 - Manufacturing information
 - Clinical protocols
 - Data from any prior human research
 - Information about the investigator
- FDA review
 - 30 days to review
 - » Approval to begin clinical trials.
 - » Clinical hold to delay or stop the investigation
 - Participants are exposed to unreasonable or significant risk.
 - Investigators are not qualified.
 - Materials for the volunteer participants are misleading.
 - The IND application does not include enough information about the trial's risks.
 - While IND open, the developer must provide the FDA new protocols, safety updates and real-time information on serious side effects. When trial is complete, study reports must be submitted.

NDA (New Drug Application) BLA (Biologics Licensign Application)

- The purpose is to demonstrate that a drug is safe and effective for its intended use
- Includes
 - Everything about a drug—from preclinical data to Phase 3 trial data—in an NDA. Developers must include reports on all studies, data, and analyses. Along with clinical results, developers must include:
 - Proposed labeling
 - Safety updates
 - Drug abuse information
 - Patent information
 - Information from studies conducted outside the United States
 - Institutional review board compliance information
 - Directions for use

• FDA Review

- Accept or refuse the application within 60 days (eg if incomplete)
- Team has 6 to 10 months to make a decision on whether to approve the drug
 - » Full review of each section by specialist (eg medical officer, statistician, pharmacologist
 - » FDA inspectors travel to clinical study sites to conduct a routine inspection. The Agency looks for evidence of fabrication, manipulation, or withholding of data.
 - » The review team issues a recommendation, and a senior FDA official makes a decision.

• FDA Advisory Committee

- If questions arise that require independent expert advice, an Advisory Committee (eg ODAC (Oncology Drug Advisory Committee)) will be convened. This also allows the public to make comments.
- FDA Approval
 - If approvable, the FDA works with applicant to develop prescribing information.
 - If issues still need to be resolved, developer requested to address questions based on existing data, or perform additional studies.

Other Terminology

- EMA (European Medicines Agency) FDA equivalent
- CDER (Center for Drug Evaluation and Research) has responsibility for prescription and nonprescription or over-the-counter (OTC) drugs.
- GCP (Good Clinical Practice) international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve the participation of human subjects.

 GLP (Good Laboratory Practice) - regulations set the minimum basic requirements for: study conduct, personnel, facilities, equipment, written protocols, operating procedures, study reports, and a system of quality assurance oversight for each study to help assure the safety of FDA-regulated product

FDA Meetings

• Opportunities to ask for help from FDA :

- Pre-IND application, to review FDA guidance documents and get answers to questions that may help enhance their research
- After Phase 2, to obtain guidance on the design of large Phase 3 studies
- Any time during the process, to obtain an assessment of the IND application, eg Clinical Pharmacology, CMC, Safety
- Not a requirement to take FDA's suggestions.
 - » As long as trials are thoughtfully designed, safeguard participants, and otherwise meet Federal standards, FDA allows wide latitude in clinical trial design.

During NDA/BLA review

Special Initiatives To Facilitate Anticancer Drug Development

- Accelerated Approval
 - Allow drugs for serious conditions that filled an unmet medical need to be approved based on a surrogate endpoint.
- Fast Track
 - Facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
- Breakthrough Designation
 - A process designed to expedite the development and review of drugs which may demonstrate substantial improvement over available therapy
- Priority Review
 - FDA's goal to take action on an application within 6 months
- Facilitating patient access to unapproved anticancer agents
- Advisory committee membership and voting rights to patients and patient representatives
- Reducing the need for IND applications for investigator-initiated studies for marketed agents in non-labeled cancer indications

FDA Programs to Expedite Drug Development & Review



Tufts CSDD 2015

The FDA and You!

Sponsor and Investigator Responsibilities

Introduction / topics

- IND / IDE
- Form 1572 / Box 9 Commitments
- Adverse event reporting

IND / IDE

- Federal oversight of interstate commerce
- Transport/sale across state lines requires license
- Exemption for drugs / devices in development



"Drug" as defined by FDA

- Substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and
- Substances (other than food) intended to affect the structure or any function of the body of man or other animals
- Note: vitamins / supplements are subject to regulation if used as a drug (to effect bodily function or health outcome)

Investigational New Drug (Application)

Complete Form 1571

- Protocol
- Product description
 - Investigator brochure / Package insert
 - Manufacturing information
 - All known safety and efficacy data
 - Cross file vs Drug Master File
- FDA has 30 days to respond ("30 day hold")
 - Approve
 - Clinical Hold more action needed
- Annual updates required

| | Next Page | Expor | rt Data | Import Dat | a | Reset Form | | |
|---|--|---|--|--|---|--|--|--|
| DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration | | | | | | Form Approved: OMB No. 0910-0014 Expiration Date: February 28, 2019 See PRA Statement on page 3. | | |
| INVESTIGATIONAL NEW DRUG APPLICATION (IND) (Title 21, Code of Federal Regulations (CFR) Part 312) | | | | | | IOTE: No drugit Inical investigat rvestigation is in | iologic may be shipped or ion begun until an IND for effect (21 CFR 312.40) | |
| 1. Name of Sponsor | | | | | | 2. Date of | Submission (mm/dd/yyyy) | |
| 3. Sponsor Address | | | | | 4 | . Telephone Nur | mber (Include country cod | |
| Address 1 (Street addres | s, P.O. box, company i | name c/o) | | | | applicable and | area code) | |
| Address 2 (Apartment, su | ute, unit, building, floor | r, etc.) | | | | | | |
| City | | State/Provi | ince/Region | | | | | |
| Country | | | ZIP or Pos | tai Code | | | | |
| Name(s) of Days (include | all available comer: 1 | Trade Gene | dr. Chamir | al or Codel | | C IND No | mbar (Forsubuch, arcino | |
| a nancia) er anag (manac | | | | [| Continuati Page for a | on IS | ner (r pressur y sarge | |
| 7. (Proposed) Indication for | Use | Is | this indicati | on for a rare dises | ase (preval | ence <200,000 ir | 1 U.S.)? 🔲 Yes 🔲 N | |
| | | D | oes this pro rphan Desig dication? | duct have an FDA mation for this | De Ind | es, provide the C signation numbe leation: | r for this Continuation Page for #7 | |
| | | | | | ~ | | | |
| 8. Phase(s) of Clinical Inves 9. List numbers of all Invest CFR Part 314.420) , and | itigation to be conduct Igational New Drug Ap Biologics License App | ted Pr splications (2 slications (21 | hase 1 | Phase 2 Pt t 312), New Drug 501) referred to in | Application this applic | Other (Specify) ns (21 CFR Part cation. | : 314) , Drug Master Files (| |
| Phase(s) of Clinical Invest List numbers of all Invest CFR Part 314.420), and IND submission should The next submission ile | isgation to be conduct igational New Drug Ap Biologics License App be consecutively numi | ted Proplications (2) plications (2) plications (2) bered. The I | hase 1 | Phase 2 Phase Phas | Application this applic ed "Serial n ed "Serial n | Other (Specify) ns (21 CFR Part cation. | 314) , Drug Master Files (Serial Number | |
| 8. Phase(s) of Clinical invest 9. List numbers of all invest CFR Part 314.420), and 10. IND submission should The next submission (e. Subsequent submission | isgation to be conduct igational New Drug Ap Biologics License App be consecutively num g., amendment, repor s should be numbered | ted Propilcations (2) plications (2) bered. The I t, or corresp d consecutiv | hase 1 21 CFR Part 6 I CFR Part 6 Initial IND st ondence) si rely in the or | Phase 2 Ph Phase 2 Ph t 312), New Drug 501) referred to in hould be numbern hould be numbern der in which they | Application http://www.application http://www.application ed "Serial In ed "Serial In vare submi | Other (Specify) ns (21 CFR Part cation. wmber: 0000." Number: 0001." tted. | 314) , Drug Master Files Serial Number | |
| 8. Phase(s) of Clinical Inves 9. List numbers of all Invest OFR Part 314.420), and 10. IND submission should The next submission (e. Subsequent submission 11. This submission contain Clinical Investigational N Results For Resct value | itigation to be conduct igational New Drug Ae Biologics License App be consecutively num g, amendment, repor s shouid be numbered s the following (Select iew Drug Application (I) on Cr Reinsteiment | ted Phoplications (2) plications (2) plications (2) bered. The I t, or corresp d consecutiv t all that app ND) | hase 1 21 CFR Part 1 I CFR PART | Phase 2 Ph Phase 2 Ph t 312), New Drug 501) referred to in hould be number hould be number rider in which they se to Clinical Hold Report | Application this applic d "Serial I ed "Serial I are submi | Other (Specify) ns (21 CFR Part cation. wmber: 0000.* Number: 0001.* ttted. lesponse To FD/ leneral Correspo | Serial Number | |
| 8. Phase(s) of Clinical Invest 9. Uld numbers of all Invest CFR Part 314.420), and 10. IND submission should The next submission Subsequent submission 11. This submission contain Initial Investigations N I Reguest For Reactivat Development Safety U | sigation to be conduct igational New Drug Ap Biologics License App de consecutively numi s should be numbered s the following (Select ew Drug Application (II ion O'r Reinstatement Iosate Report (IDSUR) | ted Ph oplications (2 plications (21 bered. The I t, or corresp d consecutiv t all that app ND) | hase 1 21 CFR Part | Phase 2 Ph Phase 2 Ph t 312), New Drug 501) referred to in hould be number hould be number der in which they se to Clinical Hold Report Specifyl: | Application this application this application ed "Serial In ed "Serial In are submi | Other (Specify) is (21 CFR Part cation. wmber: 0000.* Number: 0001.* tted. lesponse To FD/ ieneral Correspo | t 314) , Drug Master Files (Serial Number ARequest For Information notence | |
| Phase(s) of Clinical Invest CRR Part 314 A20), and CRR Part 314 A20), and The next submission school The next submission contain Subsequent submission contain This submission contain The submission contain The submission contain The submission contain The submission contain Development Safety U Protocol Amendment(is) | Isgation to be conduct Isgational New Drug Ap Biologics License App de consecutively numi s should be numbered s the following (Select ew Drug Application (II ion OF Reinstatement jotate Report (DSUR) Informatik | ted Propilcations (2) plications (2) plications (2) plications (2) t, or corresp d consecutiv t all that app ND) | hase 1 21 CFR Part 1 21 CFR Part 1 1 CFR P | Phase 2 Ph Phase 2 Ph 1312), New Drug 501) referred to in hould be number hould be num | Application this application this application of "Serial I or are submined of are submined of the subm | Other (Specify) is (21 CFR Part tation. wmber: 0000." wmber: 0001." tted. leaponse To FD/ leneral Correspo | Serial Number | |
| B. Phase(s) of Clinical Invest Uts numbers of all Invest GFR Part 314.420), and The read submission should The read submission should The read submission for the submission The submission controls The submission controls Prevent For Reached Development Sabe() Request For Reached Development Sabe() Reagest For Reached New Investgatar | stgation to be conduct igational New Drug Ap Biologics License App De consecutively num g., amendment, report s should be numbers the following (Select lew Drug Application (II ton Of Reinstatement pdate Report (DSUR) Informatis Chem Chem Chem | ted Propilcations (2) polications (2) plications (2) plications (2) plications (2) plications (2) plications (2) plications (2) t all that app ND) pn Amendin istry/Microbic iacology/Toxi ii | hase 1 | Phase 2 Pr Phase 2 Pr 1312), New Drug 501) referred to in hould be number hould be number hould be number ther in which they se to Clinical Hold Report ipeoffy: Request Propt Speci | Application Application this applic d 'Serial I are submi i | Coher (Specify) ts (21 CFR Part tablon. umber: 0000.* Vumber: 0001.* tted. leteponse To FD/ leteral Correspo e Review Accessment | Serial Number Serial Number ARequest For Information indence IND Safety Report(s) Initial Written Report Report up to a Written Report | |
| B. Phase(s) of Clinical Invest GER Part 314.420 , and CFR Part 314.420 , and IND submission about The next submission (e) Buddequest submission (e) Buddequest submission (e) Request For Reaching Profocol Amendment(s) New Protoc New Protoc New Region New Region Ne | stgation to be conduct Igational New Drug Ae Biologics License App be consecutively num , amendment, regoo s hould be numberet s the following (Sector tew Drug Application (I) too Gr Reinstatement polate Report (DSUR) Informati Pham Cinica Cinica | ted Propilcations (2) polications (2) plications (2 | hase 1 | Phase 2 Properties 2 Provided Phase 2 Properties 2 Proper | Application this applic d "Serial n ed "Serial n or e submin for ng letary Nam al Protocol al Dispute F | Cother (Specify) is (21 CFR Part attion. umber: 0000.* umber: 0001.* tted. lesponse To FD/ leneral Correspo e Review Assessment Resolution_ | Serial Number Serial Number Request For Information notice IND Bathy Report(s) Initial Written Report Report Report Report | |
| Phase(s) of Cinical Invest CFR Part 314.420 , and CFR Part 314.420 , and The next submission about The next submission (e) Subsequent submission Inth is submission contain Inth in therefugations to CFR Part 314.420 , and Development Safety U Protocol Amendmed(s) Charge in Photocol Charge in Photocol Subsequent plant Met NextSafety PAR-PHOC Protocol Subsequent plant Development Safety CFR Safety Development Safety CFR Safety Development Developm | algation to be conduct algational New Drug Are Biologics License App be consecutively num be consecutively num be consecutively num bould be number algate Resort (DSLR) informatil Cheroni 'Tappicate (Lardfor 'Tappicate (Lardfor | ted Propilcations (2) pilcations (2) pilcations (2) pilcations (2) pilcations (2) pilcations (2) t all that app ND) on Amendm stry/Microbio iacology/Tox i i Pharmacol adon statem n.) | hase 1 | Phase 2 Pr Phase 2 Pr Phase 2 Pr Phase 3 Pr Phase 2 Pr | Application Application this applic d "Serial n ed "Serial n ed "Serial n are submit I F for for for al Protocol al Dispute f application (xanaded A) | Cither (Specify) other (Specify) is (21 CRP Part attion. umber: 0000." titled. lesponse To FD/ leneral Correspondent e Review Assessment lesolution for any items se coses (Use, 10' | Serial Number Serial Number Request For Information ndence IND Bathety Report(s) Intal Written Report Pollow-up to a Written Report Report so a Written Report Report so a Written Report Report So a Serier Report | |
| B. Phase(s) of Clinical Invest GER Part 314.420), and CFR Part 314.420), and IL. IND submission should The next submission The next submission Subsequent submission II. This submission control Subsequent submission II. This submission control Development Sabtu Development Sabtu | algation to be conductively algorithm to be conductively running a standardine to the conductively running a standardine (the running cleant as the following cleant as the fo | ted Propilcations (2) popilcations (2) plications (| hase 1 21 CFR Part 1 21 CFR Part 1 1 CFR P | Phase 2 Pr Phase 2 Pr | Application Application this applik dd 'Sertal in dd 'Sert | Cither (Specify) Cither (Specify) Isological CFR Part Isological Aumber: 0000.* Aumber: 0001.* Ited. Ited. Ited. Isological Isological For Any Items se costs Use, 21 O Isological Isolo | Serial Number | |
| B. Phase(s) of Clinical Invest GER Part 314.420), and CFR | algation to be conducting agatoma New Drug Ae Biologics License App Biologics License App be consecutively numma , amendment, consecutively numma should be numbered be following (Sector March Informatia) Partia) Distribution (Sector March Cheni) Partia) Cheni) Chen | ted pplications (2) bered. The is bered. The is of the open of the | hase 1 [] CFR Part is Initial IND st CFR Part is Initial IND st CFR Part is Initial IND st CFR Part is IND st CFR Part is | Phase 2 Pr Phase 2 Pr | Application ase 3 Application ad 'Serial in this applil d'Serial in this applil d'Serial in for for for for for for al Protocol al Dispute F application al Protocol al Dispute F and | Other (Specify) Other (Specify) (Context 2) CER Part tation. (Context 2) CER Part tation. (Context 2) Context (Context 2) Cont | Serial Number Serial Number Serial Number Request For Information IND Bately Report(c) IND Report on Writer Report Repor | |
| B. Phase(i) of Clinical Invest CFR Part 314.420), and CFR Part 314.420), and IL ND submission schoold The next submission The next submission IL This submission contain Insta Investgatoria N Request For RestArd Profocol Amendment(is) New Protocol Charge Finbolog Did Charge Finbolog Did Charge Finbolog Did Charge Request, 21 Charge Request, 22 Charge Request, 22 Charge Request, 22 | algation to be conductively numeral Biologics License App Biologics License App Biologics License App and the synthesis and the synthesynthesis and the synthesynthesis and the synthesis and th | ied protections (21) polications (21) plications (21) plications (21) discrete discrete the correspondence of all that applies the correspondence of all that applies the correspondence of all that applies the correspondence of all that applies that app | hase 1 [] CFR Part is I CFR I CFR Part is I CFR I | Phase 2 PP Phase | Application ase 3 Application ad 'Serial in this applil d'Serial in ad 'Serial in ad 'Serial in ad 'Serial in ad Protocol al Dispute F application al Drotocol al Dispute F ant, Ronn- al 11 GFR 312- ant, Ronn- al 10 GFR 312- ant, Ronn- al 310(d) | Other (Specify) Other (Specify) attain (21 GFR Part attain) (esponse To FD/ lesponse To FD/ leneral Correspondent Assessment for any items se cress (Jse, 21 G point for any items se cress (Jse, 21 G profile profile (11 G profile (12 G profi | Serial Number Serial Number Serial Number NRequest For information ndence IND Safety Report(s) Initial Written Report Pollow-up to a Written Report Report Report Report Serial Suz Refer RE 912.300 CFR 312.310 Safetre IND or Protocol, OFR 312.330 | |
| B. Phase(s) of Clinical Invest GER Part 314.420), and CFR Part 314.420), and IL ND submission should The next submission Subsequent submission IT. The submission Request pro Reactive Profector Charge F Infoloci Det of Left OFR Sector PreMCPMC Protocol Select the following only to the cited OFR sector Charge Request, 21 Charge Request, 22 Charge Request, 22 Charge Request, 22 Charge Request, 22 Charge Request, 22 Charge Request, 22 CBER/DOC Receipt Stamp | stgation to be conductively numeral Biologics License App Biologics License App be consecutively numeral solution of the solution of the solution of solution and the solution of the following (Select the following (Select | ted processors of the second s | hase 1 Image: Install IND style Initial IND style Image: | Phase 2 PP Phase 2 PP Phase 2 PP Phase 3 PP | Application Application of "Serial and and and and ded "Serial In are submit of and and and and and detary Nam al Plotocid al Dispute F application serio (NR 312) detary (Nam) serio (NR 312) detary (Nam) detary (N | Other (Specify) Other (Specify) Is (21 OFR Part tation. umber: 0000.* umber: 0000.* ted. lesponse To FD/ leneral Correspondent e Review Assessment lesolution for any items se corespondent is point | Serial Number Serial Number Serial Number Request For Information Request For Information Report IND Safety Report(s) Initial Written Report Report Initial Written Report Report Report Seried below, Refer RR 912.00 Report Safeter ND or Protocol, OFR 912.30 Internation | |
| B. Phase(s) of Cinical Invest CFR Part 314.420 , and CFR Part 314.420 , and IL ND submission should The next submission (e. Subsequent submission Consequent submission Development Submission Consequent submission Development Submission Consequent submission Development Submission Development Submission Development Submission Development Submission Development Submission Development Submission Development Submission Development Submission Development Submission Development Submission Development Submission Development Submission Development Submission Development Submission Development Developmen | algation to be conductively using lighting New Drug Ac Biologics License App be consecutively numeric as should be numbered to for New Section in Control in Control Pharm Clicks Cl | International Constructions (21) (20) (20) (20) (20) (20) (20) (20) (20 | hase 1 21 CFR Part 1 21 CFR Pa | Phase 2 PP Phase 2 PP Phase 2 PP Phase 3 PP Phase | Application of "Serial in a spole of "Serial in a spole of "Serial in a spole of "Serial in a se submit in the submit is a spole of the submit in the submit is a spole of the submit in the submit is a spole of the submit in the submit is a spole of the submit in the submit is a spole of the submit in the submit is a spole of the submit in the submit is a spole of the submit in the submit is a spole of the submit is a spone of the submit is a spole of the submit is a spone | Other (Specify) to (21 OFR Part tation. umber: 0000.* umber: 0000.* umber: 0000.* ted. umber: 0000.* ted. | Serial Number Serial Number Serial Number Nequest For Information ndence IND Safety Report[s] Initial Written Report Pallow-up to a Written Report Report Pallow-up to a Written Report Report Safe Pallow-up to a Written Safe Pallow-Up to a W | |
| B. Phase(s) of Clinical Invest GER Part 314.420), and CFR Part 314.420), and CFR Part 314.420), and IL ND submission school The next submission Busbeauent submission This submission contain Intal metaglations N Request For Reaction Return of the Submission The Submission contain Request For Reaction New Protocol New Protocol New Protocol Date of CFR sectors Request protocol Charge Request, 21 Charge Request, 21 Charge Request, 21 CBER/DCO Receipt Stamp | stgation to be conducting tigational New Drug Ac Biologics License App be consecutively numma a, menotiment, rough so should be numberets a the following (Select a | ed pricedora (2 opications (2 locations (2 l | hase 1 1 21 CFR Part 1 21 CFR Part 1 11 CFR | Phase 2 PP Phase 2 PP Phase 2 PP Phase 3 PP | Application of "Serial in a spole of "Serial in a spole of "Serial in a spole of "Serial in a submit in a submit in a submit in a submit in a spole of the spole | Other (Specify) Other (Specify) Is (2) CFR Part tation. umber: 0000.* umber: 0000.* ted. lesponse To FD/ leneral Correspondent for any items se coss Use, 21 O Pol pency 1 The 21 Division Assig ND Number/ | Serial Number Serial Number Serial Number Request For Information Request For Information Report NID Safety Report(c) Inits Writen Report Rep | |

IND Exemptions for marketed drugs

In order to qualify for exemption from the requirement to obtain an IND, the following criteria must be met (21 CFR 312.2(b)):

- 1. Study not intended to support a new indication or change in labeling
- 2. Drug is lawfully marketed in the US
- 3. Does not involve route of administration, dose, patient population or other factor that would substantially increase or decrease acceptability of risk
- 4. Conducted in compliance with requirements for IRB review
- 5. Not intended to promote or commercialize the drug

Cancer considered particularly risky, thus #3 may be interpreted rather broadly

"Device" as defined by FDA

- An instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article which is:
 - intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or
 - intended to affect the structure or any function of the body of man or other animals, but does not act through chemical action within or on the body and which is not dependent upon being metabolized for its action

Significant vs Non-Significant Risk Device

- Significant Risk device is
 - Intended as an implant, or
 - Is purported to be for a use in supporting or sustaining human life, or
 - Is for a use of substantial importance in diagnosing, curing, mitigatin, or treating disease
 - and presents potential for serious risk to the health, safety, or welfare of a subject
- IDE's for NSR devices may be granted by an IRB
- IDE's for SR devices are issued by the FDA



Investigational Device Exemption

Submit form 1571

- Protocol
- Device description
 - Manufacturing information
 - All known safety and efficacy data
 - Cross file
- FDA has 30 days to respond
- Annual updates required

| | Next Page | Exp | ort Data | mpon | | 1088 | etrorm | | |
|---|---|---|--|--|---|---|---|--|--|
| DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration | | | | | Form Expire See F | Form Approved: OMB No. 0910-0014 Expiration Date: February 28, 2019 See PRA Statement on page 3. | | | |
| INVESTIGATIONAL NEW DRUG APPLICATION (IND) (Title 21, Code of Federal Regulations (CFR) Part 312) | | | | | NOTE clinica invest | : No drugit il investigat Igation is in | tiologic ma ton begun i effect (21 | y be shipped or until an IND for t CFR 312.40) | |
| 1. Name of Sponsor | | | | | | | 2. Date of | Submissio | n (mm/dd/yyyy) |
| 3. Sponsor Address | | | | | | 4. Tel | phone Nu | mber (Inclu | ide country code |
| Address 1 (Street addre | ss, P.O. box, company r | name c/o) | | | | app | ilcable and | i area code | :) |
| Address 2 (Apartment, s | suite, unit, building, floor, | , etc.) | | | | 1 | | | |
| City | | State/Pro | ovince/Regio | n | | | | | |
| Country | | | ZIP or Po | ostal Code | | - | | | |
| | | | | | | | | | |
| 5. Name(s) of Drug (Includ | e all available names: 7 | Trade, Ge | neric, Chem | ical, or Code) | Contin Page 1 | uation for #5 | 6. IND NU | mber (if pr | eviously assign |
| 7. (Proposed) Indication fo | r Use | | is this indica | ation for a rare | disease (pri | evalence | <200,000 | n U.S.)? | 🗌 Yes 🔲 N |
| | | | Does this pr Orphan Des Indication? | oduct have an signation for thi | IFDA Is | f yes, p Designa Indicatio | rovide the (tion numbe n: | Orphan Infor this | Continuation Page for #7 |
| enase(s) or canical live List numbers of all lives | tigation to be conducts | ed 🔲 | Phase 1 | Phase 2 | Phase 3 | oth ations (2 | er (Specify | (1). | o Master Files (|
| Private(s) or Clinical life List numbers of all Inves CFR Part 314.420) , and | estigation to be conducte stigational New Drug Ap d Biologics License Appl | plications (| Phase 1 2 (21 CFR Par 21 CFR Par | Phase 2 Arr 312), New 1 t 601) referred | Phase 3 Drug Applics d to in this a | ations (2 pplication | er (Specify I CFR Part |): : 314) , Dru | g Master Files (|
| mase(s) or clinical live List numbers of all lives CFR Part 314.420), and IND submission should The next submission (s Subsequent submission) | stigation to be conducts stigational New Drug Ap d Biologics License Appl Libe consecutively numb ±.g., amendment, report ne schucib e numbered | plications (lications (bered. Th t, or corre | Phase 1 2 (21 CFR Par (21 CFR Par e Initial IND (spondence) tively in the | Phase 2 The second seco | Phase 3 Drug Applica d to in this a mbered "Ser mbered "Ser | Oth ations (2 pplication fal numb rial Numb | er (Specify I CFR Part I. er: 0000." ver: 0001." |): : 314) , Dru Serial Nu | g Master Files (Imber |
| masters) or clinical life List numbers of all Invest CFR Part 314.420 , and IND submission should The next submission (Subsequent submission 11. This submission contail | stigation to be conducts stigational New Drug App d Biologics License Appl 5 be consecutively numb 1.g., amendment, report ns should be numbered ns the following (Select | ed plications (lications (bered. Th t, or correct d consecu | Phase 1 [(21 CFR Par (21 CFR Par)(21 CFR Par (21 CFR Par)(21 CFR | Phase 2 The second should be num order in which | Phase 3 Drug Applica d to in this ay mbered "Sen mbered "Sen they are su | other ations (2 pplication tal numb rial numb | er (Specify I CFR Part I. er: 0000.* ier: 0001.* |): 314) , Dru Serial Ni | g Master Files (Imber |
| e maters) or Clinical live Ust numbers of all Invest CFR Part 314.420 , and TR next submission (Subsequent submission Inits submission contail Inits submission contail Inits livestigational | estigation to be conducte stigational New Drug Api d Biologics License Appl d be consecutively numb e.g., amendment, report ins should be numbered ns the following (Select New Drug Application (II) | ed plications (plications (lications (bered. Th t, or corre d consecu al that a ND) | Phase 1 21 CFR Pa 21 CFR Par 21 C | Phase 2 Phase 2 The second sec | Phase 3 Drug Applica d to in this a mbered "Ser mbered "Ser mbered "Ser hey are su | isi numb domitted. | er (Specify I CFR Part). er: 0000.* ver: 0001.* | I: 314) , Dru Serial Ni A Request i | g Master Files (unber For information |
| a. materia) of LimitAl link 5. List numbers of all Invest CFR Part 314.420), and The next submission should The next submission Subsequent submission 11. This submission contai II. Inits ubmission contai II. Inits ubmission contai II. Inits ubmission Development Safety | estigation to be conducts stigational New Drug App d Biologics License Appl d biologics Licen | ed plications (plications (lications (bered. Th t, or correct consecutive all that a) ND) | Phase 1 [(21 CFR Por (21 CFR Par (21 CFR Par)(21 CFR Par (21 CFR Par)(21 CFR | Phase 2 Phase 2 The set of the se | Phase 3 Drug Applici d to in this a mbered "Sen mbered "Sen they are su i they are su i Hold | ations (2 pplication fal numb fal numb domitted. Respo Gener | er (Specify I CFR Part). er: 0000." er: 0001." nse To FD; al Correspo | I: 314), Dru Serial Nu A Request i andence | g Master Files (imber For Information |
| e. rivisits) or Unital IIV S. List numbers of all Invest CFR Part 314.420 , and CFR Part 314.420 , and The next submission should The next submission Subsequent submission This submission contai This next Free Reactive Protocol Amendment(is Protocol Amendment(is | estgation to be conducts atgations New Drug App d Biologics License Appl J be consecutively numb e.g., amendment, report ns the following (Select New Drug Application (III vision OF Reinstatement Update Report (DSUR)) Informatio | ed plications (plications (lications (bered. Th t, or correct consecut all that a) ND) | Phase 1 (21 CFR Pa 21 CFR | Phase 2 The set of the | Phase 3 Drug Applics d to in this a mbered "Ser mbered "Ser "Ser "Ser "Ser "Ser "Ser "Ser "Ser | Other ations (2 pplication fal numb homitted. Respo | er (Specify I CFR Part I. er: 0000.* ier: 0001.* ier: 0001.* ier: 0001.* | I: 314) , Dru Serial Nu A Request i andence IND Safe | g Master Files () Imber For Information |
| . rusets) or curical link . rusets) or curical link . List numbers of all invest OFR Part 314.420), and the next submission should The next submission The submission rule Ital numerity and Request Por Reactive Protocol Amendmentic Net Protocol | Estigation to be conducts estigation to be conducts estigations New Drug App I be consecutively numb I be consecutively numb I be consecutively numbered ins the following (Select New Drug Application (I) Viota Report (DSUR) I Informatio I Cohemis | ed plications (plications (lications (bered. Th t, or correct all that a ND) | Phase 1 [(21 CFR Pa (21 CFR Par (21 CFR | Phase 2 at 312), New it 601) referred to 601) referred should be num should be num order in which is to Clinical i Report (Specify): | Phase 3 Drug Applics d to in this a mbered "Sen mbered "Sen they are su Hold | Coth ations (2 ppilcation ial numb rial Numb ibmitted. Respo Gener | er (Specify I CFR Part). er: 0000." wer: 0001." nse To FD, al Correspo | I: Serial Nu A Request in A Request in IND Safe IND Safe | g Master Files (imber For Information by Report(s) Written Report |
| Envised () or United () in the second of the second o | stigation to be conducts stigational New Drug An d Biologics License Appl 2 be consecutively numb 2 be consecutively numb 2 be consecutively numb 3 be consecutively numbered ns the following (Select 4 biol OF Reinslatement Update Report (DSUR) 3 information 1 Chemit 2 hannel 1 hannel 2 hannel 1 hanne | ed plications (plications (lications (bered. Th t, or correct consecut all that a ND) on Amenia stry/Micro acology/T | Phase 1 (21 CFR Par 21 | Phase 2 at 312), New II at 312), New II t 601) referred should be num should be num should be num order in which rise to Clinical II Report (Specify): Reg II F | Phase 3 Drug Applics d to in this all mbered "Sen they are su Hold [] usest for Weeting Proprietary N | Coth ations (2 pplication fal numb domitted. Gener | er (Specify I CFR Part). er: 0000." ver: 0001." inse To FD/ al Correspo //ew | I: Serial Ni A Request I andence IND Safe IND Safe IND Safe Follow Report | g Master Files (imber For Information by Report(s) Written Report t |
| Envised () or Curical Inter- Construction of Construction of Constru | stigation to be conducts stigational New Drug Ap, d Biologics License Appl De consecutively numb p.g., windmitter, report ns thouid be numbered ins thouid be numbered ins thouid be numbered to Children Colorigent information Information Children | ed plications (plications (lications (bered. Th t, or correct all that a ND) on Ameni stry/Micro acciogy/T (lications (lications (li | Phase 1 (21 CFR Par (21 CFR | Phase 2 at 312), New I at 312), New I t 501) referred should be num should be num order in which nse to Clinical I Report (Specify): Reg 1 1 5 5 5 6 7 7 7 7 7 8 9 7 7 7 7 8 9 7 7 7 7 7 7 7 | Phase 3 Drug Applics d to in this al mbered "Sen they are su Hold [] uset for Weeting Proprietary N Special Proto Formal Disp. | Other O | er (Specify) I CFR Part er: 0000.* er: 0001.* mse To FD. al Correspo (ew sament ution | Serial Ni Serial Ni A Request in andence IND Safel IND Safel Follow Report | g Master Files (umber For Information by Report(s) Written Report t |
| S. ruset programmers of all invest CFR parts 1144.20), and The new sector of the sector o | stigation to be conducts stigational New Drug Ap d Biologics License Appl 1 be consecutive) numb 1 g, amendment, report 1 a, amendment, report 1 | ed plications (plications (lications (bered. Thi , or correct consecut al that a ND) on Ameni stry/Micro acology/T (1 Pharmai ation state | Phase 1 [; (21 CFR Par (21 C | Phase 2 [interpret of the second seco | Phase 3 Drug Applicit d to in this aj mbered "Seri they are su i Hold Hold Proprietary N Special Proto Formal Dispu with applicat | Ceth ations (2 pplication fail Numth domitted. Respo Gener viame Re occi Asse viame Re occi Asse | er (Specify) I CFR Part I. er: 0000." ver: 0001." inse To FD) al Correspo (ew ssment ution ny flems se | I: Serial Ni Serial Ni A Request 1 andence IND Safel IND Safel Initial Follow Report | g Master Files (umber For Information by Report(s) Written Report t ww.Refer |
| S. rusets) or Unical Inter S. Lidt numbers of all Invest CFR Part 3144.20), non- The numbers of all Invest CFR Part 3144.20), non- The number of the number of the number Lidt number of the number of the number Descent States, and the number of the number Request For Reactive Descent States, and the number of the nu | stigation to be conducts stigation to be conducts at pational New Drug Api de Biologics License Apip s de consecutively numb s de consecutive | ed pications (incations (inc | Phase 1 (21 CFR Par (21 CFR Pa | Phase 2 [at 312), New vitat 312), New vitat 312), New vitat 501) referred to 501) referred to 501 referred vitat 501 referred vitat 1 Report (Specify): Report vitat 1 Report vitat 1 Repor | Phase 3 Drug Applics to in this at mbered "Sen mbered "Sen they are su i Hold [] [] uest for Keeting Proprietary N Special Proto Formal Dispu with applicat Expande | Centrations (2) ations | er (Specify) I CFR Part er: 0000.* ier: 0001.* ier: 0001.* ier: 0001.* ier: 0001.* ier: 0001.* ier: 0000.* ier: | It | g Master Files (imber For Information fy Report(s) Written Report t Written Report w. Refer 0 |
| E. rusets) or United Inter- S. Lidt numbers of all Inves- CFR Part 3144.20), nor- The numbers of all Inves- CFR Part 3144.20), nor- The number of the number o | stigation to be conducts stigation to be conducts atgational New Drug Api at a consecutively numb s a storust be numbered at a storust be numbered aton Or Reinstatement Update Report (DSUR) at for Archiver and a storust Calinical y If application (# Penerri Calinical y If application (Austington n for further information rich Eusegion From Intop Res 12.2 (f) | ed pications (incations (incations (consecutions (all that a) on Amenni stry(Micro cology/T i Pharman ation state 1,) | Phase 1 [(21 CFR Par (21 CFR | Phase 2 [art 312), New with t601) reference t601) reference t601) reference transmissional be numbered which is the to Clinical if Report (Specify): Req are a standard and a standard an | Phase 3 Drug Applicit d to in this a mbered "Ser mbered "Ser they are su Hold [] Hold [] Proprietary N Special Proto Formal Dispu with applicat Expande al Patent, N nor y 21 CFR | Other O | er (Spect) I CFR Part I CFR | I: | g Master Files (mber For Information ty Report(s) Written Report ww. Refer 9 Size Patient (CFR 312.315 |
| E. ruscis) of United Inter S. List numbers of all Invest CFR Part 3144.20), and The next submission should The next submission Subsequent submission Subsequent submission Subsequent submission This Investigational Next Protocol Anadamenter Request For Reactive Protocol Amendmentity Protocol Amendmentity Change In Protocol Denge In Protocol Denge In Protocol Denge In Protocol Denge In Protocol Request For Reactive Denge In Protocol Denge | Stagation to be conducts stagation to be conducts atgational New Drug Api diologics Ucense Api s beconsecutively numb s a structub e numbered s beconsecutively number s beconsecutively number beconsecutively number s beconsecutively number beconsecutively number s beconsecutively number s be | ed plications (plications (lications (d consect. Th d, or correct of consect. The d consect. The section (all that a) on Ameni stry/Nicro accology/T d Pharman action state (Pharman accology/T d Pharman accology/T d Pha | Phase 1 (21 CFR Pa (21 CFR | Phase 2 st 312), New it 501) referesc should be num should be num should be num order in which nue to Clinical i Repot (Specify): Req i d be submitted i mdividu Emerge i Individu 21 GPR | Phase 3 Drug Applica Drug Applica Drug Applica to In this a motered "See motered "See they are su Held Held Held E E E E E E E E E E E E E E E E E E E | Other O | er (Specify) I CFR Part I CFR Part I CFR Part er: 0000." I CFR Part I CF | It | g Master Files (amber For Information by Report(s) Written Report t www.Refer D Size Failent (OFR 312.315 D or Photocol, 20 |
| E. rusets) or Unical Inter S. Lidt numbers of all Invest CFR Part 314-420; num CFR Part 314-420; num CFR Part 314-420; num The next submission should The next submission Lidt Investigatorial Ital Investigatorial Intal Investigatorial Ital Investigatorial Change in Prolocol Change in Prolocol Sevent the Stillings Ital Respects of Change in Prolocol Dender in Prolocol Sevent the Stillings Ital Investigatorial Ital Inv | stigation to be conducts stigation to be conducts at a consecutively numb s a storage of the stigation of the s a storage of the stigation of the ns the tolowing (ellect ns the tolowing (ellect New Org, Application (i) tological people of the pharm charmacian of the stigation of the pharmacian of the stigation of the stigation of the pharmacian of the stigation of the stigation of the stigation of the stigation of the stigation of the stigation of the stigation of the stigation of the stigation of the stigation of the stigation of the stigation of the stigation of the stigation of the stigation of the stigation of the stigation of the stigation of the stigation of the stig | ed pications (ications (ication | Phase 1 [121 CFR Par 121 CFR | Phase 2 stouid be num shouid | Phase 3 Drug Application Drug Applicati | ore tations (2 pplications (2 p | er (Specify) I CFR Part I CFR PAR | R 314) , Dru 314) , Dr | g Master Files (umber For Information by Report(s) Written Report t Written Report t Written Report t Size Patient O FR 312.315 D or Protocol, 20 |
| S. rusets) of United Inter S. Ust numbers of all invest CFR parts 1144.20), and The next submission should The next submission Subsequent submission Charge In Automation Development Safety Protocol Amendmenting Development Safety Protocol Amendmenting Development Safety Protocol Amendmenting Development Safety Protocol Amendmenting Development Safety Protocol Amendmenting Development Safety Charge In Protocol Development Safety Charge In Protocol Development Safety Charge Respects CeBER/DOC Recept Stamp | stigation to be conducts stigation to be conducts all biologics Ucense Appl d biologics Ucense Appl to a should be numbered ins the toilowing (Geter web Orup Application (# storn of Reinstatement UodaR Report (DBUR)) Informatio C Crinical () Informatio C Crinical) Informatio () Informatio () Informatio () Crine () Informatio () Crine () C | ed pications (ications (ications (corrections (correct | Phase 1 [121 CFR Par 121 CFR | Phase 2 rt 312), New 1 st 312), New 1 st 301) referred should be nur | Phase 3 Drug Application Drug Application To the this application Hold [[[[[[[[[[[[[[[[[[[| Other State S | er (Specify) I CFR Part I CFR Part er 10000.* er 10001.* er 1 | 2. 314), Dru Serial Ni ARequest I IND Safel IND Safel Follow Report Re | g Master Files (mber For Information ty Report(s) Written Report Written Report Size Patient I CFR 312.315 D or Protocol, 20 |
| E. rusets) or Unical Inter List numbers of all Invest CFR Part 314-420; and The next submission should The next submission contail Inter submission contail Inter Investigational Inter Investigational Itale Investigation | stigation to be conducts stigation to be conducts aligational New Drug Api diologics License Api ab e consecutively numb e g., amendment, report ns the following (Beter ns the following (Beter New Drug Application (I) to Cr Reinstement Update Report (DSUR) Phamm Clinical C | ed plications (plications lications (bered. Th t, or corner is consecu ND) on Amenic acology/T i Pharman adon staty/Micro adon staty Pharman DDR Re | Phase 1 [121 GFR Pt 1 | Phase 2 Fits 2 | Phase 3 Drug Application To page 4 Drug Application To page 4 Drug Application To page 4 Drug 4 Dru | Cetrations (2 pplication ial numb ial Num ial | er (Specify) I CFR Part I CFR Part er: 0000.° er: 0001.° er: 0001.° mse To FD. al Correspo dew sament ution ny items se al Correspo dew sament ution ny items se al CFR Part ne To FD. al CFR Part er: 0001.° | I: 314), Dru Serial Ni Request i IND Safe IND Safe Follow Report Repor | g Master Files (unber For information ty Report(s) Written Report Written Report Written Report Size Patient 0 Patient 0 Patient 20 Patient |

FDA Form1572

- Investigator contract
- Required for all investigators in FDA-regulated research
- Documentation of qualifications
- Contact information for responsible parties
- "Box 9 Commitments"
 - Acknowledgement of Investigator responsibilities

| | 1. NAME AND ADDREI Name of Clinical Investi | (See Instructions on reverse side. | OR (CFR) PART 312) .) | NOTE: No investigation unti a completed, sign FDA 1572 (21 C) | t: OMB No. 0910-0014 t: February 28, 2019 sment on Reverse. aligetor may participate in an ali harbe provides the aponsor w gned Statement of Investigator, F FR 312.53(e)). | |
|--|--|---|-----------------------------|---|--|--|
| Name of Clinical Investigator Address 1 Address 2 City Bitate Province/Region Country DIP or Postal Code DIP COUNTRY DIP or Postal Code DIP CPUCKING, TRAINING, AND EXPERIENCE THAT CUULURY THE INVESTIGATION AS AN EXPERT IN THE CUUCUL, INVESTIGATION O THE CIRCUP OR THE USE UNDER INVESTIGATION. ONE OF THE FOLLOWING IS PROVIDED (Seed on of the Bibling) Control UNDE Control UNDE Country DIP of Postal Code DIP OF Statement of Qualifications DIP OF Statement OF Statem | Name of Clinical Investi | SS OF INVESTIGATOR | | | | |
| Address 1 Address 2 City Bitate Province/Region Country ZIP or Postal Code Country ZIP or Postal Code Country | | gator | | | | |
| Oty Blate/Province/Region Country ZIP or Postal Code 2: EDUCATION, TRAINING, AND EXPERIENCE THAT OUALIPY THE INVESTIGATOR AS AN EXPERT IN THE CLINICAL INVESTIGATOR O THE DRUG FOR THE USE LIDDER INVESTIGATION, ONE OF THE FOLLOWING IS PROVIDED Clearch and the failuring.) Country Clinical class of the failuring.) 3: NAME AND ADDRESS OF ANY MEDICAL SCHOOL, HOSPITAL, OR OTHER RESERVICH FACILITY Country Country Country 3: NAME AND ADDRESS OF ANY MEDICAL SCHOOL, HOSPITAL, OR OTHER RESERVENT of Qualifications Country Country Country Country Address 1 Address 2 City Blate/Province/Region Country ZIP or Postal Code Address 1 Address 2 City Blate/Province/Region Country ZIP or Postal Code Address 1 Address 2 City Blate/Province/Region Country ZIP or Postal Code Address 2 City Blate/Province/Region Country ZIP or Postal Code Stream of Clinical Laboratory Pacity Country ZIP or Postal Code Contry State/Province/Region Country ZIP or Postal Code Country State/Province/Region Country ZIP or Postal Cod | Address 1 | | Address 2 | | | |
| City Bate/Province/Region Country ZIP or Postal Code 2. EDUCATION, TRAINING, AND EXPERIENCE THAT OULLIPY THE INVESTIGATIOR AS AN EXPERT IN THE CLAUCAL INVESTIGATION OF THE DRUG FOR THE USE UNDER INVESTIGATION, ONE OF THE FOLLOWING IS PROVIDED (Select ans of the following.) Image: Country investigation of the following.) 3. INVER AND ADDRESS OF ANY MEDICAL SCHOOL (NOSTIGATION A) OR OF THE FOLLOWING IS PROVIDED (Select ans of the following.) CONTINUATION FAG (Investigation of the following.) 3. INVER AND ADDRESS OF ANY MEDICAL SCHOOL (NOSTIGATIONS) WILL BE CONDUCTED WHERE THE CLAUCAL INVESTIGATIONS) WILL BE CONDUCTED CONTINUATION FAG (Investigation of the Research Facility) Address 1 Address 2 Contry ZIP or Postal Code (Investigation of Contry) ZIP or Postal Code (Investigation of Contry) Contry ZIP or Postal Code (Investigation of Contry) A NUME AND ADDRESS OF ANY CLINICAL LABORATIORY FACILITIES TO BE USED IN THE STUDY CONTINUATION FAG (Investigation of Contry) CONTINUATION FAG (Investigation of Contry) ZIP or Postal Code (Investigation of Contry) Contributation FAG (Investigation of Contry) 5. INVER AND APPROVINCE REGION Contry Contry CONTINUATION FAG (Investigation of Contry) Contry (Investigation o | | | | | | |
| 2 EDUCATION, TRAINING, AND EXPERIENCE THAT QUALIFY THE INVESTIGATOR AS AN EXPERT IN THE QUALIFY THE INVESTIGATION OF THE FOLLOWING IS PROVIDED (Sections of the filtering) Curricul Vitae Curricul Vitae Curricul Vitae Curricul Vitae Curricul Vitae Count Vitae | City | State/Prov/nce/Region | Country | | ZIP or Postal Code | |
| The Undor Hori He Use Under Hinke In Ministry (Indone United Produced Jacket and the Moning) Curricul Vitae Curricul Vitae Mare AND ADDRESS OF ANY REDICAL SCHOOL, HOSPITAL, OR OTHER RESEARCH FACILITY Research Market School, Hospital, or Other Research Facility Address 1 Address 2 City State/Province/Region County ZIP or Postal Code Address 2 City State/Province/Region County ZIP or Postal Code Contry ZIP or Postal Code State/Province/Region County ZIP or Postal Code Address 2 City State/Province/Region County ZIP or Postal Code Contry ZIP or Postal Code Address 1 Address 2 City State/Province/Region County ZIP or Postal Code Contry Control Contry ZIP or Postal Code Control Contry ZIP or Postal Code Control Contry ZIP or Postal Code Control Contro Control Control Control Control Control Contro | 2. EDUCATION, TRAIN | ING, AND EXPERIENCE THAT QUALIFY THE | E INVESTIGATOR AS AN | EXPERT IN THE CLI | NICAL INVESTIGATION OF | |
| ANNE AND ADDRESS OF ANY MEDICAL SCHOOL, HOSPITAL, OR OTHER RESEARCH FAGILITY CONTINUATION ING MARE AND ADDRESS OF ANY MEDICAL SCHOOL, HOSPITAL, OR OTHER RESEARCH FAGILITY Morene THE CLINICAL INVESTIGATIONS INILLS BE CONCOLORD Address 2 City State-Province/Region Country ZIP or Postal Code State-Province/Region State-Province/Region Country ZIP or Postal Code State-Province/Region State-Province/Reg | THE DRUG FOR TH | Curriculum Vitae | Other Statemer | t of Qualifications | ste knowing.) | |
| MARE AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR SUMME AND ACCRESS OF THE INSTITUTIONAL R | | | | | | |
| Name of Medical School, Hospital, or Other Research Facility Address 1 Address 1 Address 2 Oty State/Province/Region Country ZIP or Postal Code State/Province/Region Country Country ZIP or Postal Code State/Province/Region Country Count | 3. NAME AND ADDREI WHERE THE CLINK | 35 OF ANY MEDICAL SCHOOL, HOSPITAL, (CAL INVESTIGATION(S) WILL BE CONDUCT | OR OTHER RESEARCH F | ACILITY | CONTINUATION PAGE for item 3 | |
| Address 1 Address 2 City State/Province/Region Country ZIP or Postal Code 4. NAME AND ADDRESS OF ANY CLINICAL LABORATORY FACILITIES TO BE USED IN THE STUDY CONTINUATION FAG Is Marke of Clinical Laboratory Facility Address 1 Address 2 City State/Province/Region Country ZIP or Postal Code S. MAVE AND ADDRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR CONTINUATION FAG Is MAVE AND ADDRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR CONTINUATION FAG Is Marke AD ADDRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR CONTINUATION FAG Is Marke AD ADDRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR CONTINUATION FAG Is Marke AD ADDRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR CONTINUATION FAG Is Marke AD ADDRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR CONTINUATION FAG Is MAVE AND APPROVED FOR THE STUDY (IES) | Name of Medical School | al, Hospital, or Other Research Facility | | | | |
| City State Province Region Country ZIP or Postal Code 4. NAME AND ADDRESS OF ANY CLINICAL LABORATORY FACILITIES TO BE USED IN THE STLDY CONTINUATION FAG Internet of Clinical Laboratory Facility Address 1 City State Province Region Country ZIP or Postal Code 5. NAME AND ADDRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR CONTINUATION FAG In Name of IRB Address 1 Address 1 Address 2 City State Province Region Country ZIP or Postal Code City State Province Region Country City State Province Region C | Address 1 | | Address 7 | | | |
| City State Province/Region Country ZIP or Postal Code 4. NAME AND ADDRESS OF ANY CLINICAL LABORATORY FACILITIES TO BE USED IN THE STUDY CONTINUATION FACILITIES TO BE USED IN THE STUDY Contract Continuation FACILITIES TO BE USED IN THE STUDY Contract Continuation FACILITIES TO BE USED IN THE STUDY Contract Contract Context | | | | | | |
| 4. NAVE AND ADDRESS OF ANY CLINICAL LABORATIORY FACILITIES TO BE USED IN THE STUDY CONTINUATION FACI Some of Clinical Laboratory Facility Address 1 Address 2 City Bate/Province/Region Country ZIP or Fostal Code CONTINUATION FACI To The STUDY/IES Address 2 City State/Province/Region Country ZIP or Fostal Code Country ZIP or Fostal Code City State/Province/Region Country ZIP or Fostal Code City State/Province/Region Country ZIP or Fostal Code City State/Province/Region Country ZIP or Fostal Code City City State/Province/Region Country ZIP or Fostal Code City | City | State/Prov/nce/Region | Country | | ZIP or Postal Code | |
| Name of Clinical Laboratory Pacitity Address 1 Address 2 City State/Province/Region Country ZIP or Postal Code S. NAUE AND ACCRESS OF THE INSTITUTIONAL REVIEW BOARD (URB) THAT IS RESPONSIBLE FOR REVEW MOD APPROVAL OF THE STUDYIES) CONTINUATION PAGE Name of IRB Address 2 Country ZIP or Postal Code Address 1 Address 2 Country ZIP or Postal Code City State/Province/Region Country ZIP or Postal Code | 4. NAVE AND ADDREI | SS OF ANY CLINICAL LABORATORY FACILIT | TIES TO BE USED IN THE | STUDY | CONTINUATION PAGE | |
| Address 1 Address 2 City State-Province/Region Country ZIP or Postal Code SNAME AND ADDRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR REVIEW AND APPROVAL OF THE STUDYIES Name of IRB Address 1 Address 2 City State/Province/Region Country ZIP or Postal Code | | | | | for item 4 | |
| Address 1 Address 2 City State/Province/Region Country ZIP or Postal Code S NAME AND ACORESS OF THE INSTITUTIONAL RELIEV BOARD (IRB) THAT IS RESPONSIBLE FOR CONTINUATION FAG REVEW AND APPROVAL OF THE STUDY(IES) Name of IRB Address 1 Address 2 City State/Province/Region Country ZIP or Postal Code | Name of Clinical Labora | story Facility | | | | |
| Oty State/Province/Region Country ZIP or Postal Code 5. NAVE AND ACRESS OF THE INSTITUTIONAL RELIEV BOARD (IRB). THAT IS RESPONSIBLE FOR CONTINUATION FAG for them 5 CONTINUATION FAG for them 5 Name of IRB Address 1 Address 2 City State/Province/Region Country ZIP or Postal Code | Address 1 | | Address 2 | | | |
| Output Deality Deality <thdeality< th=""> Deality <thdeality< th=""> <thdeality< th=""> <thdea< td=""><td>0h/</td><td>State/Bro/sce/Region</td><td>Country</td><td></td><td>7IP or Postal Code</td></thdea<></thdeality<></thdeality<></thdeality<> | 0h/ | State/Bro/sce/Region | Country | | 7IP or Postal Code | |
| S. INVIE AND ADDRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR CONTINUATION FAG for Ikin 5 CONTINUA | | charact rounce region | country | | 21 01 000 000 | |
| Nexter IN ADJ AMMOUND UP THE STUDITIES) In them 5 Address 1 Address 2 City State Province/Region Country 2IP or Postal Code | 5. NAME AND ADDRE | SS OF THE INSTITUTIONAL REVIEW BOARD | (IRB) THAT IS RESPON | SIBLE FOR | CONTINUATION PAGE | |
| Address 1 Address 2 City Blate/Province/Region Country 2IP or Postal Code | Name of IRB | OVAL OF THE STUDY(IES) | | | for item 5 | |
| Address 1 Address 2 City State/Province/Region Country 2IP or Postal Code | | | | | | |
| City State Province/Region Country ZIP or Postal Code | Address 1 | | Address 2 | | | |
| | City | State/Province/Region | Country | | ZIP or Postal Code | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | CO | A TINUALITON PAGE - TOF Item t | |
| CONTINUATION PAGE - for her | 7. NAME AND CODE N | IUMBER, IF ANY, OF THE PROTOCOL(8) IN | THE IND FOR THE STUD | r(IES) TO BE COND | UCIED BY THE INVESTIGAT | |
| CONTINUATION PAGE - for the 7. NAME AND CODE NUMBER, IF MAY, OF THE PROTOCOUS) IN THE IND FOR THE STUDY(ES) TO BE CONDUCTED BY THE INVESTIG | | | | | | |
| CONTINUATION MARE - for then 7. INVICE AND CODE NUMBER, IF ANY, OF THE PROTOCOL(S) IN THE IND FOR THE STUDY(ES) TO BE CONDUCTED BY THE INVESTIG | | | | | | |
| CONTINUATION PROF - for the 7. INVIE AND CODE NUMBER, IF ANY, OF THE PROTOCOUS) IN THE NO FOR THE STUDY (JES) TO BE CONDUCTED BY THE INVESTIG | | | | | | |
| CONTINUATION PAGE - for the 7. NAME AND CODE NUMBER, IF MAY, OF THE PROTOCOLIS) IN THE IND FOR THE STUDY(IES) TO BE CONDUCTED BY THE INVESTIG | | | | | | |

9. COMMITMENTS

I agree to conduct the study(ies) in accordance with the relevant, current protocol(s) and will only make changes in a protocol after notifying the sponsor, except when necessary to protect the safety, rights, or welfare of subjects.

I agree to personally conduct or supervise the described investigation(s).

I agree to inform any patients, or any persons used as controls, that the drugs are being used for investigational purposes and I will ensure that the requirements relating to obtaining informed consent in 21 CFR Part 50 and institutional review board (IRB) review and approval in 21 CFR Part 56 are met.

I agree to report to the sponsor adverse experiences that occur in the course of the investigation(s) in accordance with 21 CFR 312.64. I have read and understand the information in the investigator's brochure, including the potential risks and side effects of the drug.

I agree to ensure that all associates, colleagues, and employees assisting in the conduct of the study(ies) are informed about their obligations in meeting the above commitments.

I agree to maintain adequate and accurate records in accordance with 21 CFR 312.62 and to make those records available for inspection in accordance with 21 CFR 312.68.

I will ensure that an IRB that complies with the requirements of 21 CFR Part 56 will be responsible for the initial and continuing review and approval of the clinical investigation. I also agree to promptly report to the IRB all changes in the research activity and all unanticipated problems involving risks to human subjects or others. Additionally, I will not make any changes in the research without IRB approval, except where necessary to eliminate apparent immediate hazards to human subjects.

I agree to comply with all other requirements regarding the obligations of clinical investigators and all other pertinent requirements in 21 CFR Part 312.

Safety Reporting in Clinical Trials

Adverse Event

- Any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related (21 CFR 312.32(a))
- AKA Adverse Experience
- Any unfavorable and unintended sign, symptom or disease temporally associated with the use of a drug
- Does not imply or require evidence of causality
- *Investigator* identifies and reports the AE to the sponsor

Adverse Event Severity

- AE can be mild, moderate, severe, life threatening, or result in death
- By convention and convenience, cancer study AE's graded according to

Common Terminology Criteria for Adverse Events (CTCAE)

Version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010)

| Blood and lymphatic system disorders | | | | | | | | | | |
|--|--|------------------------------------|------------------------------------|-------------------------------------|--------|--|--|--|--|--|
| Bioou and rymphatic system disorders | | | | | | | | | | |
| | Grade | | | | | | | | | |
| Adverse Event | 1 | 2 | 3 | 4 | 5 | | | | | |
| Anemia | Hemoglobin (Hgb) <lln -="" 10.0<="" td=""><td>Hgb <10.0 - 8.0 g/dL; <6.2 - 4.9</td><td>Hgb <8.0 g/dL; <4.9 mmol/L;</td><td>Life-threatening consequences;</td><td>Death</td></lln> | Hgb <10.0 - 8.0 g/dL; <6.2 - 4.9 | Hgb <8.0 g/dL; <4.9 mmol/L; | Life-threatening consequences; | Death | | | | | |
| | g/dL; <lln -="" -<="" 6.2="" <lln="" l;="" mmol="" td=""><td>mmol/L; <100 - 80g/L</td><td><80 g/L; transfusion indicated</td><td>urgent intervention indicated</td><td></td></lln> | mmol/L; <100 - 80g/L | <80 g/L; transfusion indicated | urgent intervention indicated | | | | | | |
| | 100 g/L | | | | | | | | | |
| Definition: A disorder characterize | ed by an reduction in the amount of | of hemoglobin in 100 ml of blood. | Signs and symptoms of anemia ma | ay include pallor of the skin and m | ucous | | | | | |
| membranes, shortness of breath, | palpitations of the heart, soft syst | olic murmurs, lethargy, and fatiga | bility. | | | | | | | |
| Bone marrow hypocellular | Mildly hypocellular or <=25% | Moderately hypocellular or >25 - | Severely hypocellular or >50 - | Aplastic persistent for longer | Death | | | | | |
| | reduction from normal cellularity | <50% reduction from normal | <=75% reduction cellularity from | than 2 weeks | | | | | | |
| | for age | cellularity for age | normal for age | | | | | | | |
| Definition: A disorder characterized by the inability of the bone marrow to produce hematopoietic elements. | | | | | | | | | | |
| Disseminated intravascular | - | Laboratory findings with no | Laboratory findings and | Life-threatening consequences; | Death | | | | | |
| coagulation | | bleeding | bleeding | urgent intervention indicated | | | | | | |
| Definition: A disorder characterized by systemic pathological activation of blood clotting mechanisms which results in clot formation throughout the body. There is an increase in the | | | | | | | | | | |
| risk of hemorrhage as the body is depleted of platelets and coagulation factors. | | | | | | | | | | |
| Febrile neutropenia | - | - 1 | ANC <1000/mm3 with a single | Life-threatening consequences; | Death | | | | | |
| | | | temperature of >38.3 degrees C | urgent intervention indicated | | | | | | |
| | | | (101 degrees F) or a sustained | | | | | | | |
| | | | temperature of >=38 degrees C | | | | | | | |
| | | | (100.4 degrees F) for more than | | | | | | | |
| | | | one hour. | | | | | | | |
| Definition: A disorder characterize | ed by an ANC <1000/mm3 and a | single temperature of >38.3 degre | es C (101 degrees F) or a sustaine | ed temperature of >=38 degrees C | (100.4 | | | | | |
| degrees F) for more than one hou | Jr. | | | | | | | | | |
| | | | | | | | | | | |

CTCAE v4.03, June 2010

Suspected Adverse Reaction (SUSAR)

- Any AE for which there is a reasonable possibility that the drug caused the event (21 CFR 312.32(a))
- "reasonable possibility" means there is evidence to suggest a causal relationship
- *Sponsor* is responsible for making determination regarding causality
Unexpected Events

- AE or SUSAR is unexpected if
 - Not listed in investigators brochure (not previously observed)
 - Occurs with greater frequency or severity than previously identified
 - Does not mean "unanticipated" for patient / disease
- Applies to specific drug, not class

Serious Adverse Events (SAE)

- AE or SUSAR is *serious* (21 CFR 312.32(a)) if it results in:
 - Death
 - Life-threatening adverse event
 - Inpatient hospitalization or prolongation of existing hospitalization
 - Persistent or significant incapacity or substantial disruption in ability to conduct normal life functions
 - Congenital anomaly / Birth defect
 - Other events may be serious if requires medical or surgical intervention to prevent one of the outcomes listed above.
- Investigator or sponsor may determine event is serious

Investigators vs. Sponsors

Investigator

Investigator means an individual who actually conducts a clinical investigation

• Sponsor

 Sponsor means a person who takes responsibility for and initiates a clinical investigation. The sponsor may be an individual or pharmaceutical company, governmental agency, academic institution, private organization, or other organization

Sponsor-Investigator

 Sponsor-Investigator means an individual who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered or dispensed

21 CFR 312.3(a)

Sponsor Responsibilities

- Report all potentially serious risks from clinical trials or other sources
 - Report to FDA and all investigators to whom sponsor is supplying the drug
 - Report within 15 calendar days
- Evaluate event in context of other related reports or events known to sponsor
- Conduct ongoing safety evaluations including periodic review and analysis of entire safety database

Sponsor *Reporting* Responsibilities

- Sponsor must report as IND safety report within 15 days:
 - Serious and Unexpected Suspected Adverse Reaction
 - Serious
 - Unexpected
 - Suspected Adverse Reaction
 - Findings from other sources
 - Other studies
 - Findings from animal or In Vitro testing
 - Increased occurrence of SUSAR

Investigator Responsibilities

- Record all *relevant* Adverse Events
- Report Serious Adverse Events to Sponsor ASAP
- Reports required to IRB
 - Harm experienced by subject which was unexpected and at least possibly related
 - Identified new or increased risk (sponsor report, publication, new IB, etc)

Sponsor-Investigator Responsibilities

- Sponsor-investigators required to comply with responsibilities of *both* sponsors and investigators
- Responsible for reporting to
 - FDA
 - Other investigators
 - IRB

Thank You



Tufts Clinical and Translational Science Institute

Compliance Issues

Doug Reichgott, MS

Director, Financial and Regulatory Operations/Policy Tufts Medical Center



Tufts Clinical and Translational Science Institute

Compliance Issues for Clinical Research

- Conflict of Interest
- Insurance Billing



Goals

- Understand Regulations, Policies, and Procedures Related to Conflict of Interest Disclosure
- Understand Regulations, Policies, and Procedures Related to Insurance Billing for Subjects Enrolled in Clinical Research Projects





Conflict of Interest



Conflict of Interest

Widespread physician interaction with industry

- -Total 94%
- -Consulting 26% (lead authors 34%)
- Very small amounts can be influential
- Unconscious, unintentional bias
- Individuals often unaware of bias

Dana J, Loewenstein G. A Social Science Perspective on Gifts to Physicians from Industry. *JAMA*. 2003;290;252-255. Campbell E, Blumenthhal, D et al. A National Survey of Physician-Industry Relationships. *NEJM*. 2007;356:1742-50.



COI Management Issues

- Reporting level
 - -Consulting v. Pens
- Institutional v. Personal
- Non Financial
- Management Plans Effectiveness
- Multiple Policies



"Promoting Objectivity in Research" 42 CFR Part 50 Subpart F http://www.gpo.gov/fdsys/pkg/FR-2011-08-25/pdf/2011-21633.pdf



Who?

SENIOR/KEY PERSONNEL

- $-\mathsf{PI}$
- -Senior/Key personnel
 - Designated by Institution in the grant application or any other report submitted to the PHS



What?

Significant Financial Interests

- -Spouse
- -Dependent children

Related to Institutional Responsibilities

- -Research
- -Clinical
- -Education
- -Service on panels



Significant Financial Interest

Publicly traded entity:

- Remuneration received in the twelve months preceding disclosure exceeds \$5,000.
 - Salary
 - Consulting
 - Speaking
 - Authorship

-Equity exceeds \$5,000

- stock
- stock options



Significant Financial Interest (cont.)

Non-Publicly Traded Entity

- -remuneration received in the twelve months preceding the disclosure exceeds \$5,000
- -any equity interest
- Intellectual property rights
 - -Upon receipt of income.
 - -Not if through hospital



Not Significant Financial Interest

NOT SFI

- -Mutual funds and retirement accounts
- -Federal, state or local government agency
- -Institution of higher education
- -Academic teaching hospital
- -Medical Center
- Research institute that is affiliated with an Institution of higher education



Not Significant Financial Interest

Support provided by your institution

- -Grant Salary Support
- -Travel reimbursement
- -IP distribution

If the check comes from Tufts Medical Center it is NOT a Significant Financial Interest



Not Allowed

Sponsor Recruitment Bonuses

- -In-Kind
- Recruitment Bonuses to physicians



When?

- Annual Disclosure
- Update within 30 days of any change
- At time of submission of grant or IRB application



How?

Annual and Grants –eRES

• IRB

-Submitted to IRB/reviewed by institutional COI committee



Definition of FCOI

- An SFI that could directly and significantly affect the design, conduct, or reporting of research.
- Determined by institutional committee.
- Investigators submit SFI, institution determines
 COI.
- All COI must be made available upon written request.



Research COI committee

• CSO

- Research VP
- Chair of Medicine
- Compliance Representative
- Director of Research Policy



What if a COI determination is made?

Report

- Mitigation plan
 - -Disclosure
 - -Review by outside party
 - -Removal of Conflict
- May be asked to not serve as PI



Sub-Recipients

- Certify they have a Compliant COI policy Or
- Provided a policy



Training

Required least every 4 years

- -Or if policy changes
- -Or if they are found to be out of compliance





Summary

- Significant Financial Interest (SFI) disclosure.
- Related to Institutional Responsibilities.
- \$5,000
- Report SFI/Institution determines COI
- Training Every 4 years
- eRES

Hospital Policy v. Research Policy





Insurance Billing for Clinical Research



Clinical Research Ancillary Care Billing Compliance

• Emory University to Pay \$1.5 Million To Settle False Claims Act Investigation

- -August, 2013
- Emory billed Medicare and Medicaid for activities performed during clinical trial participation despite the fact that the sponsor of the trials had already agreed to pay those costs.



Rush Medical Center \$1 Million

University of Alabama \$3.4 Million

Tenet HealthCare \$1.9 Million



GAO reports federal government wasted \$125 billion in 2014 alone



Requirement

- A Medicare Coverage Analysis (MCA) must be completed for every study that includes patient care.
- Includes a Medicare Qualifying Analysis (MQA) and Billing Grid.
 - For industry studies, prior to contract execution
 - For non-industry studies, prior to activity set-up
 - We recommend prior to submission
 - Applies to all studies/patients regardless of insurance
 - All subjects need to treated the same



Medicare Coverage Analysis (MCA) Process

Qualifying Study Review (Is it a qualifying clinical trial)



Operationalize


Clinical Trial Policy

National Coverage Decision (NCD) for Routine Costs in Clinical Trials (310.1)

www.cms.hhs.gov/clinicaltrialpolicies/

Two Main Points

- 1. 10 standards for a study to qualify
- 2. Billing is allowed for "Routine Services"

(Devices are under a separate law)



Medicare Coverage Analysis (MCA) Process

Qualifying Study Review (Does the study meet the 10 standards?)









The First 7 Standards

- 1. The principal purpose of the trial is to test whether the intervention potentially improves the participants' health outcomes;
- 2. The trial is well-supported by available scientific and medical information or it is intended to clarify or establish the health outcomes of interventions already in common clinical use;
- 3. The trial does not unjustifiably duplicate existing studies;
- 4. The trial design is appropriate to answer the research question being asked in the trial;
- 5. The trial is sponsored by a credible organization or individual capable of executing the proposed trial successfully;
- 6. The trial is in compliance with Federal regulations relating to the protection of human subjects; and
- 7. All aspects of the trial are conducted according to the appropriate standards of scientific integrity.



"Deemed Studies"

Deemed studies automatically cover these 7 (Must fit **one** of these categories)

- Trials funded by NIH, CDC, AHRQ, CMS, DOD, and VA or
- Trials supported by centers or cooperative groups that are funded by these groups

or

 Trials conducted under an investigational new drug application (IND)

or

Drug trials that are exempt from having an IND



The Other 3 Standards

Must meet all of these standards

 Investigate an item or service that falls within a Medicare benefit category

and

• Enroll patients with diagnosed disease

and

 Be designed with therapeutic intent (primary endpoint of efficacy/effectiveness)



What if a Study is NOT Qualifying?

• NOTHING CAN BE BILLED TO INSURANCE



State Law

- Affordable Care Act says (in principal) that these requirements apply to all insurers, not just Medicare
 - They don't have to pay for investigational treatment, drug or device



Medicare Coverage Analysis (MCA) Process







So What is Covered?

Routine Costs

- Conventional care
 - Items or services that are typically provided absent a clinical trial

• Detection, prevention and treatment of complications

•Administration of the investigational item

Just because it can, doesn't mean it has to

MEDICARE GIVETH & MEDICARE TAKETH AWAY



Who Has This Information?

- Physicians!
- They need to sign off on documents that items are routine.



Additional Thoughts

olf it is only to assess inclusion/exclusion it CANNOT be billed

- •All subjects must be the same
- •Medicare will pay for subject injury

• REMEMBER

- If it isn't ROUTINE CARE, it can't go to insurance
- If it is paid for by the sponsor, it can't go to insurance
- If it is listed in the consent form as FREE, it can't go to insurance



Two More Thoughts

•No paying co-pays

•No sponsor payments in the case of insurance denial (payer of last resort)



 Clearly shows what can be billed to insurance and what must be paid by the study funds

Start with the "Chart of Events"

or

 Start with Study Budget and change from \$ figures to Insurance or Research



The Lottery Test

IF YOU WIN A BILLION DOLLARS AND NEVER COME BACK TO WORK WE NEED TO KNOW WHAT CAN BE BILLED WHERE



| Procedure | V1 | V2 | V3 |
|---------------|----|----|----|
| Consent | Х | | |
| Physical | X | X | Х |
| CBC | X | X | х |
| Chest X-Ray | | X | Х |
| MRI | | Х | Х |
| Drug Infusion | | X | x |
| LFTs | | X | Х |
| PK | | X | Х |



| Procedure | V1 | | |
|---------------|---------|---------|---------|
| Consent | Study - | | |
| Physical | Study | Study | Study |
| СВС | Study | Routine | Routine |
| Chest X-Ray | | Study | Routine |
| MRI | | Study | Routine |
| Drug Infusion | | Routine | Routine |
| LFTs | | Routine | Routine |
| РК | | Study | Study |



| Procedure | V1 | V2 | V3 |
|------------------------|-------|---------|---------|
| Consent | Study | | |
| Physical | Study | → Study | Study |
| СВС | Study | Routine | Routine |
| Chest X-Ray PAID BY ST | | Study | Routine |
| MRI | | Study | Routine |
| Drug Infusion | | Routine | Routine |
| LFTs | | Routine | Routine |
| PK | | Study | Study |



| Procedure | V1 | Inclusion Only | | |
|--------------------|---------|----------------|---------|--|
| | | | | |
| Consent | Study | | | |
| Physical | Study | Study | Study | |
| CBC | Study 🖌 | Routine | Routine | |
| Chest X-Ray | | Study | Routine | |
| MRI | | Study | Routine | |
| Drug Infusion | | Røutine | Routine | |
| LFTs | | Røutine | Routine | |
| PK | | Study | Study | |
| "Standard of Care" | | | | |



Research Only

| Proce | dure | M | | V2 | V3 |
|---------------|-------------|--------------|-----------------|---------|--------------|
| Consent | | Study | $\overline{/}$ | | |
| Physical | | Study | $\overline{\ }$ | Study | Study |
| CBC | | Study | | Routine | Routine |
| Chest X-Ray | | | \mathcal{N} | Study | Routine |
| MRI | | | | Study | Routine |
| Drug Infusion | | | | Routine | - Routine |
| LFTs | | | | Routine | Routine |
| PK | Administra | tion of | | Study | Study |
| | Investigati | onal Item | \nearrow | | |
| | | | | | |
| | F | Follow up fo | or | | |
| | ł | Known Toxi | city | | Tufts Medica |

| Procedure | V1 | V2 | V3 |
|---------------|-------|---------|---------|
| Consent | Study | | |
| Physical | Study | Study | Study |
| CBC | Study | Routine | Routine |
| Chest X-Ray | | Study | Routine |
| MRI | | Study | Routine |
| Drug Infusion | | Routine | Routine |
| LFTs | | Routine | Routine |
| PK | | Study | Study |



Medicare Coverage Analysis (MCA) Process









Document Agreement

- Make sure all the documents agree
 - Billing Grid
 - Budget
 - Watch for items that can be billed to insurance that are paid by sponsor
 - -Consent Form
 - Watch for "Free", "At No Cost". Make sure it is clear what will be billed to insurance
 - Contract



Who Needs to Know?

- Administrator
- Pl
- Coordinators
- Schedulers
- Ancillary Departments



Medicare Coverage Analysis (MCA) Process









Medical Center Systems

- Complete Pre-registration Forms
- Follow Ancillary Care Provider systems (Radiology/Cardiology)
- Check for Errors
- Follow-up on Amendments



Questions?

Douglas Reichgott Director of Financial and Regulatory Operations, Director of Neely Center for Clinical Cancer Research

Research Administration

617-636-5609 dreichgott@tuftsmedicalcenter.org



Thank You



Overview of Next Session

March 10, 2017 8th Floor Conference Room 35 Kneeland Street





| Meeting Agenda Clinical Trial Oversight | | | | |
|--|-----------------|--|--|--|
| Registration | 12:30 - 1:00 PM | | | |
| Neely Center for Clinical Cancer Research Doug Reichgott and Elizabeth Grimm | 1:00 – 1:30 PM | | | |
| Multi-Center Clinical Trials Karen Freund and Susan Parsons | 1:30 – 2:15 PM | | | |
| Break & Snack | 2:15 - 2:30 PM | | | |
| Cooperative Group Studies Jack Erban & Susan Parsons | 2:30 – 3:15 PM | | | |
| Data Management Tools Robin Ruthazer | 3:15 – 3:45 PM | | | |
| Panel Discussion Andy Evens, Bob Martell, Wasif Saif, Susan Parsons, Andreas Klein | 3:45 – 4:30 PM | | | |
| Conclusion Andy Evens | 4:30 – 5:00 PM | | | |



Pre-Work

No Pre-Work!

